ANVS
Annovis Bio, Inc.
$2.28
+0.88%
2026-05-08
About Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Key Fundamentals
Forward P/E
-1.68
EPS (TTM)
$-1.40
ROE
-220.6%
Profit Margin
0.0%
Price/Book
3.69
Beta
1.26
Market Cap
$79.3M
Avg Volume (10D)
1.1M
Recent Breakout Signals
No recent breakout signals detected for ANVS.
Recent Price Range (60 Days)
60D High
$3.03
60D Low
$1.54
Avg Volume
804K
Latest Close
$2.28
Get breakout alerts for ANVS
Sign up for Breakout Scanner to receive daily notifications when ANVS triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Annovis Bio, Inc. (ANVS) is listed on the New York Stock Exchange (NYSE). Breakout Scanner monitors ANVS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ANVS operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.